None
Quote | Palatin Technologies Inc. (NYSE:PTN)
Last: | $1.83 |
---|---|
Change Percent: | -2.66% |
Open: | $1.88 |
Close: | $1.88 |
High: | $1.96 |
Low: | $1.8231 |
Volume: | 20,188 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
News | Palatin Technologies Inc. (NYSE:PTN)
Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross Proceeds PR Newswire CRANBURY, N.J. , June 21, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing fi...
Palatin Announces the Initiation of a Phase 2 Clinical Study of Bremelanotide Co-Administered with a PDE5i for the Treatment of Erectile Dysfunction (ED) PR Newswire In ED patients that do not respond to PDE5i monotherapy ~30-40% of ED patients do not respond to PDE5...
Message Board Posts | Palatin Technologies Inc. (NYSE:PTN)
Subject | By | Source | When |
---|---|---|---|
HW says worth 75$ let start with 20$ | zeusgodmd | investorshub | 04/28/2023 5:09:07 PM |
Nice buys by me today longer term pay | zeusgodmd | investorshub | 04/28/2023 4:36:22 PM |
Amen brother. :) | chantillylive | investorshub | 04/24/2023 1:15:34 PM |
$Article on bio pharm companies cheap and getting | zeusgodmd | investorshub | 04/21/2023 11:49:22 AM |
Decent move on preliminary quarterly results for Vyleesi. | mike1986 | investorshub | 04/19/2023 6:11:58 PM |
News, Short Squeeze, Breakout and More Instantly...
Palatin Technologies Inc. Company Name:
PTN Stock Symbol:
NYSE Market:
Palatin Technologies Inc. Website:
Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross Proceeds PR Newswire CRANBURY, N.J. , June 21, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing fi...
Palatin Announces the Initiation of a Phase 2 Clinical Study of Bremelanotide Co-Administered with a PDE5i for the Treatment of Erectile Dysfunction (ED) PR Newswire In ED patients that do not respond to PDE5i monotherapy ~30-40% of ED patients do not respond to PDE5...
Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity PR Newswire Co-Administration Phase 2 study of bremelanotide with tirzepatide (GLP-1) to provide key information for melanocortin treatments of obesity Topline data expected by end...